Rev Esp Quimioter 2022;35(Suppl.1):43-45

New evidence in severe pneumonia: meropenem-vaborbactam

MARÍA FORTEZA GUILLOT, MARÍA MARTÍN CEREZUELA, PAULA RAMÍREZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.10.2022

The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options. Meropenem-vaborbactam has shown great efficacy against this type of microorganism, both from a clinical and microbiological point of view. Its good pharmacokinetics, including in the lung, and its safety profile make meropenem-vaborbactam an excellent therapeutic option. Finally, the absence of resistance genesis during treatment seems to indicate that its efficacy will be long-lasting.

Rev Esp Quimioter 2022; 35(Suppl. 1):43-45 [Full-text PDF]